Scholarlink

<p>Given the substantial degree of inter-individual variability in treatment responses in patients with inflammatory bowel disease (IBD), treatment optimization is warranted. We provide an overview of pharmacogenetic variants that can affect the efficacy or toxicity of drugs commonly used for IBD. We used The Danish Register of Medical Product Statistics for information about medical treatment from 2000 – 2024. Of the most used drugs Azathioprine, Mesalazine, and Sulfasalazine have pharmacogenetic recommendation guidelines and/or FDA annotations. Approximately 19,241 Danish individuals treated with azathioprine—around 801 annually—may carry a genetic variant for which pharmacogenetic dosing guidelines exist. Up to 13,934 Danish individuals using infliximab or adalimumab (~580 individuals each year) have a potential risk of developing immunogenicity related to monoclonal antibodies. This study shows the possibilities of pharmacogenetic testing as a supportive clinical decision tool to optimize treatment and minimize risk of e.g., serious adverse effects, remission, and other serious complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential of pharmacogenetics in treatment of chronic inflammatory diseases – a danish report overview from 2000 – 2024

  • 期刊论文

  • 发表日期：

    2026年2月24日

查看全文
  • Trine Andresen,
  • José A. G. Agúndez,
  • Hela Nazari,
  • Vibeke Andersen

摘要

Given the substantial degree of inter-individual variability in treatment responses in patients with inflammatory bowel disease (IBD), treatment optimization is warranted. We provide an overview of pharmacogenetic variants that can affect the efficacy or toxicity of drugs commonly used for IBD. We used The Danish Register of Medical Product Statistics for information about medical treatment from 2000 – 2024. Of the most used drugs Azathioprine, Mesalazine, and Sulfasalazine have pharmacogenetic recommendation guidelines and/or FDA annotations. Approximately 19,241 Danish individuals treated with azathioprine—around 801 annually—may carry a genetic variant for which pharmacogenetic dosing guidelines exist. Up to 13,934 Danish individuals using infliximab or adalimumab (~580 individuals each year) have a potential risk of developing immunogenicity related to monoclonal antibodies. This study shows the possibilities of pharmacogenetic testing as a supportive clinical decision tool to optimize treatment and minimize risk of e.g., serious adverse effects, remission, and other serious complications.